Our Final Offer (Maybe)! That's a FACT!

There are two rules in negotiations. Don't be the first to name a number and don't get in a bidding war with yourself. Biogen Idec (Nasdaq: BIIB  ) has broken both of them.

Back in September, Biogen made an unsolicited public offer to buy partner Facet Biotech (Nasdaq: FACT  ) for $14.50 per share. Biogen knocked down its original $15-per-share offer to the board after Facet licensed a phase 1 drug from Trubion Pharmaceuticals (Nasdaq: TRBN  ) . At the time, Biogen characterized the $14.50 as an "extremely attractive opportunity" for Facet's shareholders.

Apparently not attractive enough. Investors sent Facet's shares above that level and haven't looked back. Facet's board urged investors to reject the tender offer, and, with shares trading well above the tender offer level, why wouldn't they? If they wanted to sell their shares, they'd do it on the open market, not to Biogen for a lower price.

Yesterday, Biogen sweetened the offer to $17.50 per share, a 21% increase. That's nearly double what Facet was trading at before it made its public offer. In a letter to Facet's shareholders, Biogen says that this is its "best-and-final offer." Biogen has licensed 50% of Facet's multiple sclerosis drug daclizumab and doesn't "intend to overpay for the rest."

That values Facet at about $440 million, which is a decent price for a company with a couple of phase 2 drugs, but Biogen is still getting a pretty good deal considering that the company comes with $325 million in cash and equivalents -- and no debt -- seeded after its spinoff from PDL Biopharma (Nasdaq: PDLI  ) .

Anyone else want to play? Bristol-Myers Squibb (NYSE: BMY  ) ? You've been doing some strategic acquiring, recently. No? How about Johnson & Johnson (NYSE: JNJ  ) ? You already own part of Elan (NYSE: ELN  ) , Biogen's partner for another MS drug.

Ah, well. Hopefully Biogen doesn't continue down this damaging road of bidding against itself. After all, there are plenty of other biotech bargains out there.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Elan is a Motley Fool Rule Breakers recommendation. Johnson & Johnson is an Income Investor pick. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1059664, ~/Articles/ArticleHandler.aspx, 4/18/2014 12:09:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement